1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Greece Pharmaceuticals and Healthcare Report Q2 2015

Greece Pharmaceuticals and Healthcare Report Q2 2015

  • April 2015
  • -
  • Business Monitor International
  • -
  • 100 pages

Includes 3 FREE quarterly updates

BMI View:
Since the election of the Syriza party in early 2015, Greece has seen considerable escalation in both political and economic uncertainty. This will limit the implementation of reform in the health sector and exacerbate the already high operational risks borne by drugmakers. While BMI believes that Greece will eventually reach a settlement with international creditors and remain in the eurozone, the uncertainty during the interim will be a costly obstacle to the country's economic recovery and to the development of the pharmaceutical and healthcare sectors over our forecast period.


Headline Expenditure Projections
- Pharmaceuticals: EUR4.955bn (USD6.64bn) in 2014 to EUR4.851bn (USD5.336bn) -2.1% in local currency terms and -19.6% in US dollar terms. Forecast down from Q115.
- Healthcare: EUR14.34bn (USD19.21bn) in 2013 to EUR13.73bn (USD15.10bn) in 2014 -4.2% in local currency terms and -21.4 in US dollar terms. Forecast down from Q115.

Table Of Contents

Greece Pharmaceuticals and Healthcare Report Q2 2015
BMI Industry View ... 7
SWOT 9
Political . 11
Economic ... 12
Operational Risk . 13
Industry Forecast .. 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Greece 2011-2019) . 15
Healthcare Market Forecast .. 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Greece 2011-2019) . . 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Greece 2011-2019) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Greece 2011-2019) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Greece 2011-2019) . . 19
Patented Drug Market Forecast . 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Greece 2011-2019) 21
Generic Drug Market Forecast .. 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Greece 2011-2019) . 23
OTC Medicine Market Forecast . 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Greece 2011-2019) . . 25
Pharmaceutical Trade Forecast . 25
Table: Pharmaceutical Trade Data And Forecasts (Greece 2013-2019) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Greece 2013-2019) . . 27
Key Risks To BMI's Forecast Scenario . 27
Macroeconomic Forecasts ... 29
Economic Analysis ... 29
Table: Economic Activity (Greece 2009-2018) 34
Industry Risk Reward Ratings .. 35
Central And Eastern Europe Risk/Reward Index 35
Greece Risk/Reward Index 41
Rewards ... 41
Risks 42
Market Overview ... 43
Industry Trends And Developments 44
Epidemiology 44
Healthcare Sector .. 45
Healthcare Sector Developments ... 49
Healthcare Insurance .. 51
Research and Development .. 52
Clinical Trials ... 53
Regulatory Development .. 54
Regulatory Developments 54
Regulatory Regime 54
Intellectual Property Regime 55
Pricing Regime .. 56
Reimbursement Regime ... 58
Competitive Landscape 61
Pharmaceutical Retail Sector ... 62
Company Profile 64
Pfizer 64
Sanofi 66
Novartis . 68
GlaxoSmithKline . 70
Merck Sharp and Dohme . 72
Alapis Pharma 74
Elpen 76
Genesis Pharma .. 78
Kleva 80
Lavipharm .. 81
Pharmathen 83
Vianex ... 85
Abbott Laboratories . 87
Demographic Data 89
Demographic Forecast . 89
Table: Population Headline Indicators (Greece 1990-2025) 90
Table: Key Population Ratios (Greece 1990-2025) . 90
Table: Urban/Rural Population and Life Expectancy (Greece 1990-2025) 91
Table: Population By Age Group (Greece 1990-2025) . 91
Table: Population By Age Group % (Greece 1990-2025) . 92
Glossary . 94
Methodology .. 96
Pharmaceutical Expenditure Forecast Model .. 96
Healthcare Expenditure Forecast Model . 96
Notes On Methodology 97
Risk/Reward Index Methodology ... 98
Index Overview .. 99
Table: Pharmaceutical Risk/Reward Index Indicators . 99
Indicator Weightings 100

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.